Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -2.17% 45.00 55,631 15:22:18
Bid Price Offer Price High Price Low Price Open Price
44.00 46.00 46.00 44.50 46.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.74 -3.63 -5.70 7
Last Trade Time Trade Type Trade Size Trade Price Currency
15:29:17 O 698 44.02 GBX

Netscientific (NSCI) Latest News

More Netscientific News
Netscientific Investors    Netscientific Takeover Rumours

Netscientific (NSCI) Discussions and Chat

Netscientific Forums and Chat

Date Time Title Posts
30/11/202015:49NetScientific PLC2,631
19/9/202006:20NETSCIENTIFIC8
15/6/201910:31Netscientific16

Add a New Thread

Netscientific (NSCI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Netscientific trades in real-time

Netscientific (NSCI) Top Chat Posts

DateSubject
01/12/2020
08:20
Netscientific Daily Update: Netscientific Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 46p.
Netscientific Plc has a 4 week average price of 43.50p and a 12 week average price of 43.50p.
The 1 year high share price is 69.50p while the 1 year low share price is currently 0.75p.
There are currently 14,916,122 shares in issue and the average daily traded volume is 110,314 shares. The market capitalisation of Netscientific Plc is £6,712,254.90.
16/11/2020
18:12
kingston78: Consolidation of shares is usually a prelude to a disaster to the share price. The reverse is also true to bonus (split) shares. A strong company will have a high share price to the extent that investors find it difficult to buy in any meaningful quantity (this is psychological) so the company splits the shares say, from 1 to 10 shares (same value), but as there is pent up demand the share price after the split continues to go up. Unfortunately NetScientific consolidated its shares to make it look more respectable, but to no avail.
12/11/2020
07:47
fart_conductor: I have no knowledge to pass on nsci, i admit i speculatively jumped onto the buy button, on reading properly as i should have the 5.7% wasn't going to lift this share price far although a positive rns and frankly i'll pass, gl hope it picks up
11/11/2020
14:13
tomboyb: etScientific PLC PDS updates on Versamune based COVID-19 vaccine 11/11/2020 2:10pm UK Regulatory (RNS & others) Netscientific (LSE:NSCI) Intraday Stock Chart Wednesday 11 November 2020 Click Here for more Netscientific Charts. TIDMNSCI RNS Number : 0210F NetScientific PLC 11 November 2020 NetScientific plc ("NetScientific" or the "Company") PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune(R)-Based COVID-19 Vaccine PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency London, UK - 11 November 2020 - NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced progress on its co-development program with Farmacore Biotechnology for a Versamune(R)-based vaccine aimed at preventing COVID-19 infection. Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune(R)-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021. "PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19," said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology. "PDS Biotech and Farmacore are now one step closer to advancing our Versamune(R)-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generation vaccine in planned human clinical trials in partnership with Farmacore and to advance our understanding of the potential of novel Versamune(R)-based vaccines like PDS0203 to provide long-term protection against infection with viruses such as SARS-CoV-2." NetScientific holds approximately 5.75% of PDS' undiluted share capital. The full details of the announcement are set out below and can be found he re: hxxps://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/454-iotechandarmacorennouncepdatestooevelopmen20201110 # # #
09/10/2020
21:04
the stigologist: This 50 minute presentation and Q&A on PDSB is a great watch Can see why NSCI regarded PDSB as the highest potential of their US Game Changing Technologies ($2-4bn Mkt Cap) Cancer and covid vaccines Great partners hTtps://twitter.com/NobleFinancial/status/1312030015568195586?s=20 I own both NSCI and PDSB
07/10/2020
10:53
the stigologist: If you think the spike potential is only 80-90 then I'm afraid you don't know this stock The last time I worked out the 'see through' value of their underlying Private + Listed holdings I got to a figure of c.180p SOTP value I believe any of ProAxsis, PDS Bio or Glycotest could account for the current share price by themselves so we actually have 3 shots at Company makers Current Mkt Cap is £9m 2 guys own c.50% They aren't going to get rich by selling out to PIs they will get rich by delivering exits and liquidity events in those Companies Glycotest strikes me as biggest potential but PDS Bio (which I also own $PDSB on NASDAQ) is also hugely interesting given a competitor Vaccibody is valued at circa $1bn and just did a $700m deal with Roche Genentech
18/9/2020
20:15
fatgreek: PDSB share price looking a lot better
06/8/2020
10:29
kingston78: It is common for AIM companies to raise fresh capital by way of a placing, which is quicker and cheaper than a rights issue. The placing price is always lower than the prevailing share price to attract investors. This does not necessarily mean that the share price will drift lower. I have seen instances where a well funded company after a placing goes on to succeed because it has the funds to invest. I hope this is the case with NSCI.
05/8/2020
07:08
the stigologist: Remember folks NSCI reckoned PDSB could be worth £4 Billion 7% of £4 Billion is £280m ie this small bit of NSCI portfolio by itself could be worth what 400p a share to NSCI shareholders in that dream scenario ? Can't rule anything out in crazy covid times if we have the vaccine silver bullet
20/7/2020
20:37
baz9707: 100m mkt cap PDSB 7m to NSCI share price will be in double figures.
16/4/2020
19:27
the stigologist: I don't think it is any surprise that We've had new Management (entrepreneurial Chatham House fellow Dr Iliev) Dr Iliev joins PDS Biotech Board PDS Announced change of strategy to target COVID19 I think the reason the NSCI share price looks like it might 'overshoot' fundamental value is that the market (and insiders) may think NSCI is now set to ADD VALUE to its holdings rather than be a passive investor. Glycotest seems to me to be the seriously big driver. Earlier NSCI Investor presentations suggested valuation potential for Glycotest of c.$400m IF (big IF) NSCI achieve that then their holding in Glycotest will be worth c.$200m Versus current NSCI Mkt Cap of £12m Many people have suggested ProAxsis might be a Covid play. It might be a secondary one. Could create some excitement. On that I'm yet to be convinced.
Netscientific share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
NSCI
Netscienti..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201201 19:09:41